{"disease":{"id":"clonal-cytopenia-of-undetermined-significance","name":"clonal cytopenia of undetermined significance"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06295965","title":"Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT02958462","title":"Pre-myeloid Cancer and Bone Marrow Failure Clinic Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04102423","title":"CHIP/CCUS Natural History Protocol","phase":"","overall_status":"RECRUITING","enrollment_count":306,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT05641831","title":"Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Uma Borate","has_results":false},{"nct_id":"NCT06802146","title":"Early Intervention in High Risk CCUS","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":108,"lead_sponsor_name":"Lachelle D. Weeks, MD, PhD","has_results":false},{"nct_id":"NCT04902833","title":"Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT03418038","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06063486","title":"Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT05030441","title":"Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT05483010","title":"Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":16,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT06240754","title":"Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT06566742","title":"A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05102370","title":"A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}